NEW YORK (Reuters Health) - A new study has dashed hopes that intermittent dosing of BRAF inhibitor dabrafenib and the MEK inhibitor trametinib would be as effective as continuous dosing of the drugs ...

Please provide your email address to receive an email when new articles are posted on . More than half of patients assigned the combination remained recurrence free at 5 years. “The 5-year data are ...

Please provide your email address to receive an email when new articles are posted on . Patients with a stage III melanoma mutation treated with dabrafenib plus trametinib had longer restricted mean ...

Phase III studies of single agent therapy in metastatic melanoma with BRAF V600 mutations meet primary endpoints Findings from GlaxoSmithKline (GSK) plc's Phase III clinical study programme evaluating ...

The German Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether the drug combinations of dabrafenib plus trametinib and of encorafenib plus binimetinib have an added ...

The combination is the first and only therapy to be approved with a tumor-agnostic indication in both children and adults with solid tumors that have a BRAF V600E mutation, Novartis said late ...

GlaxoSmithKline plc (LSE:GSK) today announced that the US Food and Drug Administration (FDA) has granted Priority Review designation to its supplemental New Drug Applications (sNDAs) for combined use ...

The largest known prospective study of patients treated with trametinib plus dabrafenib for unresectable advanced melanoma with BRAF-V600 mutation confirmed the combination’s clinical activity.

First approved combination of oral targeted therapies for unresectable or metastatic melanoma with BRAF V600E or V600K mutations[1] LONDON, Jan. 8, 2014 /PRNewswire via COMTEX/ -- GlaxoSmithKline plc ...

The latest report from a phase III clinical trial investigating patients with BRAF V600K/E mutated unresectable stage IIIC or IV melanoma reveals that patients receiving a combination of dabrafenib ...

Determining the optimal treatment sequence for patients with BRAF V600 mutant metastatic melanoma was the focus of the DREAMseq phase 3 clinical trial. The combination of nivolumab and ipilimumab (N/I ...

To treat melanoma, the most serious type of skin cancer, doctors have turned to surgery, chemotherapy, radiation therapy, and even immunotherapy, among other treatment options. Yet when it ...